Image Analysis Group (IAG), a leader in clinical trial imaging and artificial intelligence-driven biomarkers, has taken a significant step to enhance its operations in the United States by inaugurating a new office in Cambridge, Massachusetts. This strategic location in the Boston area is designed to bring IAG’s teams for operations and business development into closer proximity with biotechnology and pharmaceutical firms, thereby facilitating stronger partnerships and offering localized support for clinical trials in this high-profile region.
With this new establishment, IAG is poised to bolster its efforts across multiple therapeutic domains, including oncology, neuro-oncology, radiopharmaceuticals, immunology, as well as rheumatic and metabolic diseases. The Cambridge office is positioned to foster closer collaboration with sponsors and contract research organizations involved in the crucial phases of clinical trials, particularly those that are heavily reliant on imaging technology. IAG’s expansion is also set to create new employment opportunities in the area, with plans to recruit talent in clinical imaging operations, data science, regulatory support, and business development over the coming 12 to 24 months.
This office will be integral to IAG’s comprehensive imaging services, encompassing consultation on clinical trial design, optimization of imaging protocols, centralized image analysis, and the delivery of data in compliance with regulatory standards. IAG believes that embedding itself within the dynamic Boston life-sciences ecosystem will facilitate improved collaboration with key players, including biotechnology companies, pharmaceutical organizations, academic entities, and clinical research centers.
IAG’s global operations span North America, Europe, and the Asia-Pacific region, where it partners with pharmaceutical, biotechnology, and medtech companies, as well as CROs, on multi-center studies. Its international framework is meticulously structured to ensure the standardization of imaging protocols, the harmonization of data, and the consistency of imaging analysis across global trials.
Founded in 2007 and headquartered in London, Image Analysis Group operates as an imaging Clinical Research Organization (iCRO). It supports pharmaceutical, biotechnology, and medical technology sectors with imaging-based clinical trial endpoints. Working across various medical fields such as oncology, inflammatory diseases, musculoskeletal conditions, cardiometabolic disorders, and rare disease indications, IAG utilizes its DYNAMIKA™ platform. This technology integrates AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time oversight of clinical trials. For more information, the company can be reached via their website at www.ia-grp.com, or through their press contact, Marie Fussell.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.